jumped Tuesday after the Denmark-based drugmaker released positive test data on its treatment for intracerebral hemorrhages.
The company said a phase II-b study demonstrated that its NovoSeven treatment led to a significant reduction in hematoma growth.
In addition, results showed that patients had significantly improved neurological and functional outcomes, implying a lasting patient benefit in terms of reduced disability and dependency on help.
The company called the results a "pioneering breakthrough" and will "immediately liaise with regulatory agencies in the effort to achieve approval for the use of NovoSeven."
An intracerebral hemorrhage is the most deadly and least treatable form of stroke. Survivors experience more severe disabilities and complications than those of other forms of stroke, including loss of movement, speech and mental capability.
Shares of Novo Nordisk's
New York Stock Exchange
ADR rose $3.36, or $6.8%, to $52.66 in unusually heavy trading. Seven times the average daily volume of 25,000 shares changed hands.